Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Buys IL-2 Technology From Good, Which Forms New Firm Bonum

Executive Summary

Roche is paying $250m up front to buy Good Therapeutics, which will launch a new company, Bonum Therapeutics, to explore its platform technology for targets other than interleukin-2.

You may also be interested in...



Deal Watch: GSK Gets Rights To Spero’s Phase III Antibiotic

GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.

Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames

Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames

Scrip's Rough Guide To IL-2: Mother Of All Cytokines

Nektar Therapeutics, Alkermes and Roche are among the companies with new solutions for more safely targeting an old cytokine well validated in cancer immunotherapy. Top execs explain how and why.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147015

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel